Context Therapeutics Inc. is a clinical-stage biopharmaceutical company developing cancer treatments for women. Candidates include ONA-XR (onapristone extended release) to treat female hormone-dependent cancers, and CLDN6xCD3 bsAb, intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6 (Claudin 6). The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for gynaecologic cancer therapy. Context Therapeutics was incorporated in 2015 and is headquartered in Philadelphia, PA.
What is Context Therapeutics's quote symbol?
What is the 52 week high and low for Context Therapeutics (NASDAQ: CNTX)?
How much is Context Therapeutics stock worth today?
How much is Context Therapeutics's stock price per share?
What is Context Therapeutics's Market Cap?